Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02910557 · ClinicalTrials.gov registry record
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
A clinical trial, sponsored by Amgen.
- Completed
- Registry status
- 187
- Enrollment target
NCT02910557: Completed study, sponsored by Amgen.
NCT02910557 is a clinical trial that has completed, run by Amgen. The registered enrollment target is 187 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02910557 has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- 187 participants
- Enrollment target
Study Summary
A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients, close contacts, and health care providers; and long term safety in treated patients for up to 5 years after the first IMLYGIC dose.
Primary Outcome
Estimate the incidence rate of herpetic infection with detection of talimogene laherparepvec (T-VEC) DNA among patients for up to 5 years after the first IMLYGIC dose.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2017-08-10 |
| Est. Completion | 2026-01-30 |
What the finished NCT02910557 record still lists
NCT02910557 is an observational study that tracks outcomes without assigning an intervention. The registered 187 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02910557 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02910557 about?
NCT02910557 is a clinical study titled "Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection". A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients, close contacts, and health care providers; and long term safety in trea...
What is the current status of trial NCT02910557?
This trial is currently completed. The enrollment target is 187 participants. The study started on 2017-08-10. Estimated completion is 2026-01-30.
Who is sponsoring clinical trial NCT02910557?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06153251 · 187 participants · Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- NCT06254898 · 187 participants · NA
Use of Incentives for Stressful Medical Procedures
- NCT07062237 · 187 participants · NA
A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence
- NCT07217574 · 187 participants
Program in Oncology for Tribal Health Systems.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI